Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in ...

Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) significantly improved invasive ...

Some 77% of patients saw their tumours shrink, 8% saw them completely disappear, and 69% saw partial shrinkage of their tumours.

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Zongertinib received FDA approval for HER2-mutant NSCLC, showing efficacy in first-line treatment with a 77% objective ...

But awareness alone isn’t enough. In this milestone year, ACS encourages everyone to do more this October and turn awareness ...

Anbenitamab combined with chemotherapy significantly improved PFS and OS in HER2-positive gastric or GEJ cancer patients compared to chemotherapy alone. The trial showed a 75% reduction in progression ...